Y Intercept Hong Kong Ltd grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 175.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,937 shares of the medical research company's stock after acquiring an additional 5,055 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Thermo Fisher Scientific were worth $3,949,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in TMO. Norges Bank purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $3,149,754,000. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Thermo Fisher Scientific by 86.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC lifted its position in Thermo Fisher Scientific by 1,905.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC lifted its position in Thermo Fisher Scientific by 140.7% during the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after buying an additional 639,467 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO traded up $8.45 during mid-day trading on Thursday, reaching $475.16. The company had a trading volume of 5,397,278 shares, compared to its average volume of 2,492,388. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The stock has a market cap of $179.37 billion, a PE ratio of 27.87, a P/E/G ratio of 2.06 and a beta of 0.77. The company has a 50-day moving average price of $411.01 and a two-hundred day moving average price of $471.10. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.
Insider Buying and Selling at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.33% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the company. UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Evercore ISI cut their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday. Finally, Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.
Check Out Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
